Welcome to our dedicated page for Oragenics SEC filings (Ticker: OGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oragenics, Inc. (OGEN) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Oragenics is a clinical-stage biotechnology company focused on intranasal therapeutics for neurological disorders, led by its concussion and mild traumatic brain injury candidate ONP-002. Through its filings, the company discloses material agreements, financing transactions, governance changes, and details of its development strategy.
Investors can review current reports on Form 8-K to see how Oragenics documents key events such as public offerings of Series H Convertible Preferred Stock and Warrants, the entry into material agreements with its placement agent, updates on NYSE American listing compliance, settlements of disputes, and appointments and compensation of directors and executive officers. These 8-K filings also frequently incorporate press releases that summarize shareholder updates, clinical progress, and strategic partnerships.
Registration statements on Form S-1 and related amendments outline the structure and terms of Oragenics’ securities offerings, including the rights of holders of Series H preferred stock, conversion features into common stock, dividend provisions, and potential dilution. These documents also describe the company’s status as a smaller reporting company, its principal executive offices in Sarasota, Florida, and its focus on nasal delivery of pharmaceutical medications in neurology and infectious diseases.
Through this page, users can also locate exhibits referenced in filings, such as equity incentive plans, stock option award forms, at-the-market sales agreements, and key collaboration or license agreements. Together, these materials provide a detailed view of Oragenics’ capital structure, governance framework, and contractual relationships that support its ONP-002 program and intranasal platform.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand the implications of new 8-Ks, S-1 registrations, and other submissions. Real-time updates from EDGAR, combined with structured access to forms related to financings, governance, and listing compliance, allow investors to follow how Oragenics is funding and governing its clinical-stage operations over time.
Oragenics Inc reported that director Robert Koski received a grant of stock options on 12/11/2025 under the company's 2021 Equity Incentive Plan, as amended, pursuant to its non-employee director compensation program. The option covers 125,000 shares of common stock at an exercise price of $0.93 per share, equal to the closing price on the grant date. The options vest immediately, are exercisable starting 12/11/2025, and expire on 12/11/2035. Following this award, Koski beneficially owns 125,000 stock options directly.
Oragenics Inc. reported that director Charles Pope received an award of stock options as part of the company’s non-employee director compensation program. On 12/11/2025 he was granted options to buy 125,000 shares of common stock at an exercise price of $0.93 per share under the company’s 2021 Equity Incentive Plan, as amended.
The options vest immediately, making them fully exercisable from the grant date, and they expire on 12/11/2035. After this grant, Pope beneficially owns 125,000 derivative securities directly, each representing the right to purchase one share of Oragenics common stock.
Oragenics, Inc. updated compensation for its leadership. The board increased Chief Executive Officer Janet Huffman’s annual base salary by five percent from $325,000 to $341,250, effective January 1, 2026, and awarded her a cash bonus of $110,500 based on performance under the existing compensation program.
The board also granted Huffman stock options to purchase 250,000 shares of common stock at an exercise price of $0.93 per share, vesting in equal annual installments over three years, with earlier vesting upon a change in control. Each non-employee director received options for 125,000 shares at $0.93 per share that vested immediately, and director Natasha Giordano received an additional onboarding stock option award valued at $30,000 when she joined the board.
A holder of OGEN common stock has filed a notice of proposed sale under Rule 144. The filing covers the planned sale of 210 shares of common stock through Goldman Sachs & Co. LLC on the NYSE, with an aggregate market value of
Oragenics, Inc. filed a current report to note that it has issued a new press release for shareholders. On November 12, 2025, the company released an update describing recent developments that took place during the third quarter of 2025 and shortly afterward. The report states that this press release is being furnished as an exhibit and incorporated by reference, directing readers to that document for the detailed business and operational update.
Oragenics (OGEN) filed its Q3 2025 10‑Q, reporting a net loss of $3.07 million for the quarter and $7.56 million year‑to‑date. Operating expenses were driven by higher G&A tied to legal and financing activity, including a $700,000 accrual for a legal settlement, while R&D rose modestly as the company prepared ONP‑002 for clinical work.
Liquidity improved significantly: cash and equivalents were $11.4 million as of September 30, 2025, reflecting a July financing of $15.2 million in net proceeds from 660,000 Series H preferred shares and accompanying warrants, and repayment of a $3.0 million short‑term note. Stockholders’ equity stood at $9.83 million. The company effected a 1‑for‑30 reverse split in June and regained NYSE American equity compliance in October.
Management continues to note substantial doubt about the company’s ability to continue as a going concern, though current cash is expected to fund operations for at least the next twelve months and support the planned ONP‑002 Phase 2a start.
Oragenics, Inc. entered a Settlement Agreement with Ladenburg Thalmann, paying $700,000 for a mutual release of all claims related to a disputed fee tied to a prior asset purchase. This resolves arbitration between the parties.
The company also regained compliance with NYSE American continued listing standards, and the “.BC” indicator is expected to be removed at the open on October 21, 2025. Oragenics reports that stockholders’ equity exceeds $6.0 million as of October 18, 2025, satisfying Sections 1003(a)(i), (ii) and (iii).
Management cites recent financing actions: in July 2025, a public offering of Series H Convertible Preferred Stock generated $16.5 million in gross proceeds and is initially convertible into up to 9,570,000 shares of common stock, inclusive of dividends payable on the Series H Preferred Stock. Additional capital included an ATM sale on February 5, 2025 for $2.75 million gross and a September 2024 offering for $4.45 million gross.
Oragenics, Inc. appointed Natasha Giordano to its board of directors, effective September 1, 2025. She brings extensive leadership experience from prior CEO and board roles at multiple pharmaceutical and healthcare-related companies and holds a Bachelor of Science in nursing from Wagner College.
Under Oragenics’ non-employee director compensation program, which provides a $45,000 annual base fee for board service, the board agreed to pay Ms. Giordano $3,750 per month for September through December 2025. The company states there are no special arrangements or related-party transactions tied to her appointment, and she has agreed to stand for re-election at the next annual shareholder meeting.
Oragenics Inc. reporting person Natasha Giordano filed an Initial Statement of Beneficial Ownership (Form 3) related to a 09/01/2025 event. The filing lists Giordano's address in Sarasota, FL and indicates her relationship to the issuer as a Director. The form states no securities are beneficially owned by Giordano as of the filing. The document is signed by an attorney-in-fact on behalf of Giordano on 09/02/2025.
Oragenics, Inc. (OGEN) filed a Registration Statement on Form S-8 covering employee benefit plans and incorporated multiple prior registration statements and amendments by reference. The filing lists related Annual and Quarterly Reports filed through August 11, 2025, includes signatures by officers and directors dated August 25, 2025, and enumerates corporate governance and equity-plan documents and amendments being incorporated by reference, plus legal and auditor consents.
FAQ
What is the current stock price of Oragenics (OGEN)?
What is the market cap of Oragenics (OGEN)?
